Navigation Links
Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011
Date:2/4/2011

provides useful information to management and investors regarding various financial and business trends relating to our financial condition and results of operations. When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of our ongoing operating performance. In addition, these non-GAAP financial measures are among those indicators we use as a basis for evaluating operational performance, allocating resources and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP financial measures. To the extent this release contains historical non-GAAP financial measures, we have also provided corresponding GAAP financial measures for comparative purposes.

About PharmacyclicsPharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medial healthcare needs; and to identify promising product candidates based on scientific development expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has four product candidates in clinical development, a clinical development candidate in late stage preclinical evaluation and several preclinical molecules in lead optimization. We are committed to high standards of ethics, scientific rigor, and operational efficiency as we move each of these programs to viable commercialization.

The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbo
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Pharmacyclics Announces Date of Fourth Quarter and Fiscal Year End 2009 Conference Call
2. Pharmacyclics to Present and Webcast at Upcoming Life Sciences Investor Conferences
3. Pharmacyclics, Inc. Rights Offering Oversubscribed
4. Pharmacyclics Announces Subscription Price for Rights Offering
5. Pharmacyclics to Present at the 8th Annual Needham and Company Life Sciences Conference
6. Pharmacyclics Files Registration Statement for Rights Offering
7. Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results
8. Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth
9. Pharmacyclics Secures $5.0 Million in Debt Financing
10. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
11. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Nova Scotia (PRWEB) February 27, 2015 ... been made aware of a fraudulent press release disseminated ... purporting to be from Immunovaccine. This press release states ... Gilead Science, Inc. The press release did not ... the information contained within the press release. Please ...
(Date:2/27/2015)... 27, 2015 Research and Markets ( http://www.researchandmarkets.com/research/p2ddnr/global_market ... Report of Trypsin" report to their offering. , ... at providing comprehensive data on Trypsin globally and regionally ( ... North America , Latin America ... to Trypsin This report focuses on three primary ...
(Date:2/27/2015)... SAN DIEGO , Feb. 27, 2015  Pfenex ... in the development of biosimilar therapeutics, today announced that ... San Francisco Marriott Marquis on March 2 nd ... will participate on a panel discussing the current state ... World of Biosimilars . For more ...
(Date:2/27/2015)... --  PureTech , a science and technology R&D company ... technologies in the healthcare sector, announced today the appointment ... of the Board of Directors of Sanofi, to its ... a pleasure to know Chris for many years and ... together more closely now," said Dr. Robert Langer ...
Breaking Biology Technology:Immunovaccine Disclaims Hoax Press Release 2Global Market Report of Trypsin 2014-2018 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4
... death of another star. In this case, he was a ... Unfortunately, few were around to sing his deserving praise. , ... the sudden death of biotech scientist Benjamin Frydman, who passed ... year. An Argentine by birth, Frydman was a founder of ...
... Madison-based company has found a way to attack tumors without ... , TomoTherapy announced last week that its Hi-Art System, ... in North America, including Froedtert Hospital and the ... new procedure to the hospital, but were very pleased with ...
... , Jack Links Beef Jerky will be able ... as Wal-Mart, which is requiring its suppliers to add wireless ... in Minong, Wisconsin. , ,ABC Computers, a systems integration company, ... other partners to integrate radio frequency identification, known as RFID, ...
Cached Biology Technology:An Argentine biotechman in Wisconsin 2An Argentine biotechman in Wisconsin 3An Argentine biotechman in Wisconsin 4Wisconsin doctors pinpoint cancer with TomoTherapy radiation treatment 2North-woods beef jerky maker adopts RFID to track shipments 2North-woods beef jerky maker adopts RFID to track shipments 3
(Date:2/10/2015)... Inc. (NYSE: ALR), a global leader in rapid ... ended December 31, 2014. Namal Nawana, ... "We made substantial progress in the fourth quarter ... rapid diagnostics and delivering against our financial plans.  ... January enabled us to substantially reduce our debt, ...
(Date:2/5/2015)... Jan. 26, 2015   Epic Sciences , a precision ... announced that Murali Prahalad , Ph.D., president and CEO, ... Conference (PMWC) 2015: Silicon Valley, which is taking place ... Calif. on January 26-28, 2015. ... Age as Biomarkers." Last year, Epic Sciences was a finalist ...
(Date:2/5/2015)... , Jan. 28, 2015 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... the upcoming RedChip Global Online CEO Conference on January ... Gino Pereira , CEO of NXT-ID will ... lead product, the Wocket smart wallet and its full ...
Breaking Biology News(10 mins):Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34Alere Inc. Announces Fourth Quarter 2014 Results 35Alere Inc. Announces Fourth Quarter 2014 Results 36
... COLUMBIA, Mo. About one in 3,500 people are ... retina,s visual cells that eventually leads to blindness. Now, ... link between cats and humans for two different forms ... therapies that will benefit both cats and humans. ...
... As researchers continue to examine the role ... people understand the differences among various ingredients used ... Association (CRA). Interchanging two distinctly different ingredients, such ... creates factually incorrect conclusions and misleads ,consumers. ...
... BEER-SHEVA, ISRAEL, March 4, 2009 Ben-Gurion University of ... plutonium created in large nuclear reactors, making it unsuitable ... (Am 241), a form of the basic synthetic element ... can only be used for peaceful purposes. , This ...
Cached Biology News:Cats' eye diseases genetically linked to diseases in humans 2Pure fructose frequently confused with high fructose corn syrup 2Ben-Gurion University engineers develop technique to help combat nuclear proliferation 2
Human RXR beta/NR2B2 MAb (Clone H7341) Keywords: RXRbeta, RXRbeta, Retinoid X Receptor beta...
Human SOST Affinity Purified Polyclonal Ab...
BOND ELUT MATRIX-C18, 25 mg ...
Prepared from plasminogen by activation with immobilized human uPA...
Biology Products: